NF-kB Inhibitors - 2018 Pipeline Insights with Analysis by Development Stage, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "NF-kB Inhibitors- Pipeline Insights, 2018" report has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present scenario and growth prospects across NF-kB Inhibitors.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 12+ active products with more than 10 companies involved. Some of the key players include AMG0101 of AnGes MG and Bardoxolone methyl of Reata Pharmaceuticals, and BIIB098 of Alkermes/Biogen.

Products covered by Phase

• Phase III, Phase II, Phase I
• Pre-clinical
• Inactive (Dormant and Discontinued)

Overview of pipeline development activities for NF-kB Inhibitors

• Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
• Therapeutic segmentation of products for NF-kB Inhibitors.
• The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
  

Scope

• Provides an overview of therapeutic pipeline activity for NF-kB Inhibitors across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of NF-kB Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across NF-kB Inhibitors

Key Topics Covered

1. Executive Summary
2. Overview
3. Introduction
4. Structure
5. Mechanism of Action
6. Inducers
7. Repressors
8. Clinical Significance
9. NF-kB Inhibitors
10. Pipeline Therapeutics (Active Products)
11. Pipeline Therapeutics (Inactive Products)
12. Comparative Analysis
13. Late Stage Products (Phase III)
14. Comparative Analysis
15. AMG0101: AnGes MG
16. Product Description
17. Research and Development
18. Product Development Activities
19. The list continues.
20. Mid Stage Products (Phase II)
21. Comparative Analysis
22. CPI-0610: CONSTELLATION
23. Product Description
24. Research and Development
25. Product Development Activities
26. The list continues.
27. Early Stage Products (Phase I)
28. Comparative Analysis
29. Pre-clinical Stage Products
30. Comparative Analysis
31. Therapeutic Assessment: Active Products
32. Assessment by Stage and Product Type
33. Assessment by Route of Administration
34. Assessment by Stage and Route of Administration
35. Assessment by Molecule Type
36. Assessment by Stage and Molecule Type
37. Inactive Products (Dormant & Discontinued Products)
38. Comparative Analysis
39. Appendix

Companies Featured

• AnGes MG
• Catabasis Pharmaceuticals
• Constellation
• Dendright
• Incuron
• MedDay Pharmaceutical
• Neurmedix
• Realm Therapeutics
• Reata Pharmaceuticals
• Tracon Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/jn49nn/nfkb_inhibitors?w=4